{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:27:37Z","timestamp":1772166457314,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5R43AI174393"],"award-info":[{"award-number":["5R43AI174393"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Sanaria\n                      <jats:sup>\u00ae<\/jats:sup>\n                      has pioneered production of aseptic, purified, vialed cryopreserved\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      (Pf) sporozoites (SPZ) as vaccines and for controlled human malaria infections. More than 3500 individuals have received more than 9700 injections of PfSPZ worldwide. The PfSPZ are manufactured in aseptically reared female\n                      <jats:italic>Anopheles stephensi<\/jats:italic>\n                      mosquitoes. Since PfSPZ vaccines are intended primarily for some of the most disadvantaged people in the world, keeping costs low is imperative. One approach to reducing the cost of goods is to eliminate male mosquitoes from the production process, thereby doubling the numbers of PfSPZ-producing mosquitoes per unit space. We intend to do this by creating\n                      <jats:italic>An. stephensi<\/jats:italic>\n                      with a male-lethal allele controlled by the tetracycline conditional gene expression system.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Herein, we report the first step in this process, the creation of a driver line that expresses the reverse tetracycline transactivator (rtTA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After suboptimal results using the\n                      <jats:italic>bZip<\/jats:italic>\n                      early embryonic promoter, we produced three mosquito driver lines that expressed rtTA from three different genomic loci under the early embryonic\n                      <jats:italic>vasa<\/jats:italic>\n                      promoter. Expressing the rtTA under the\n                      <jats:italic>vasa<\/jats:italic>\n                      promoter significantly increased rtTA mRNA levels compared with under\n                      <jats:italic>bZip<\/jats:italic>\n                      . We were unable to achieve homozygosity in two of these lines even after 26 generations. In a third line we observed seven distinct insertions, six of which, including one located in an intron of a protein-coding gene, were homozygous. This line achieved homozygosity after being passed through seven generations, suggesting that the insertions did not disrupt the function of any crucial genomic locus. The levels of rtTA mRNA expression in the homozygous-viable line were higher than those in the other two lines, reinforcing the idea that the inability to reach homozygosity was not due to rtTA expression levels but rather the position of the insertion. The homozygous-viable line produced ~18% more eggs per female, and a hatching rate of larvae from eggs was 39% lower than that of wild-type\n                      <jats:italic>An. stephensi<\/jats:italic>\n                      . The next step will be to cross the driver line with an effector line containing a male-linked lethal gene regulated by the tetracycline responsive element (TRE).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13071-025-07003-7","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:50:14Z","timestamp":1761655814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful insertion and expression of a tetracycline transactivator in Anopheles stephensi associated with increased egg production and decreased hatching rate"],"prefix":"10.1186","volume":"18","author":[{"given":"Ehud","family":"Inbar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishaan","family":"Samantray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Alford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Harrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tales V.","family":"Pascini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tint T.","family":"Wai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Dumetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham G.","family":"Eappen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen L.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter F.","family":"Billingsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"7003_CR1","unstructured":"Vector-borne diseases. World Health Organization 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/vector-borne-diseases#:~:text=Vector%2Dborne%20diseases%20are%20human,spread%20of%20vector%2Dborne%20diseases. Accessed 26 Sept 2024."},{"key":"7003_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4161\/hv.6.1.10396","volume":"6","author":"SL Hoffman","year":"2010","unstructured":"Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, et\u00a0al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin. 2010;6:97\u2013106.","journal-title":"Hum Vaccin"},{"key":"7003_CR3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","volume":"17","author":"MS Sissoko","year":"2017","unstructured":"Sissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, et\u00a0al. Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017;17:498\u2013509.","journal-title":"Lancet Infect Dis"},{"key":"7003_CR4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","volume":"99","author":"SA Jongo","year":"2018","unstructured":"Jongo SA, Shekalage SA, Church LWP, Ruben AJ, Schindler T, Zenklusen I, et\u00a0al. Safety, immunogenicity, and protective efficacy against controlled human malaria infection of Plasmodium falciparum sporozoite vaccine in Tanzanian adults. Am J Trop Med Hyg. 2018;99:338\u201349.","journal-title":"Am J Trop Med Hyg"},{"key":"7003_CR5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4269\/ajtmh.17-0449","volume":"98","author":"A Olotu","year":"2018","unstructured":"Olotu A, Urbano V, Hamad A, Eka M, Chemba M, Nyakarungu E, et\u00a0al. Advancing global health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, tolerability, and immunogenicity of Plasmodium falciparum sporozoites vaccine for malaria in healthy equatoguinean men. Am J Trop Med Hyg. 2018;98:308\u201318.","journal-title":"Am J Trop Med Hyg"},{"key":"7003_CR6","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.4269\/ajtmh.18-0835","volume":"100","author":"SA Jongo","year":"2019","unstructured":"Jongo SA, Church LWP, Mtoro AT, Chakravarty S, Ruben AJ, Swanson PA, et\u00a0al. Safety and differential antibody and T-cell responses to the Plasmodium falciparum sporozoite malaria vaccine, PfSPZ vaccine, by age in Tanzanian adults, adolescents, children, and infants. Am J Trop Med Hyg. 2019;100:1433\u201344.","journal-title":"Am J Trop Med Hyg"},{"key":"7003_CR7","doi-asserted-by":"publisher","first-page":"eaaz5629","DOI":"10.1126\/scitranslmed.aaz5629","volume":"12","author":"M Roestenberg","year":"2020","unstructured":"Roestenberg M, Walk J, van der Boor SC, Langenberg MCC, Hoogerwerf MA, Janse JJ, et\u00a0al. A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Sci Transl Med. 2020;12:eaaz5629.","journal-title":"Sci Transl Med"},{"key":"7003_CR8","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/cid\/ciz925","volume":"71","author":"LC Steinhardt","year":"2020","unstructured":"Steinhardt LC, Richie TL, Yego R, Akach D, Hamel MJ, Gutman JR, et\u00a0al. Safety, tolerability, and immunogenicity of PfSPZ Vaccine administered by direct venous inoculation to infants and young children: findings from an age de-escalation, dose-escalation double-blinded randomized, controlled study in western Kenya. Clin Infect Dis. 2020;71:1063\u201371.","journal-title":"Clin Infect Dis"},{"key":"7003_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4269\/ajtmh.20-0435","volume":"104","author":"SA Jongo","year":"2021","unstructured":"Jongo SA, Urbano V, Church LWP, Olotu A, Manock SR, Schindler T, et\u00a0al. Immunogenicity and protective efficacy of radiation-attenuated and chemo-attenuated PfSPZ vaccines in Equatoguinean adults. Am J Trop Med Hyg. 2021;104:283\u201393.","journal-title":"Am J Trop Med Hyg"},{"key":"7003_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S1473-3099(21)00332-7","volume":"22","author":"MS Sissoko","year":"2021","unstructured":"Sissoko MS, Healy SA, Katile A, Zaidi I, Hu Z, Kamate B, et\u00a0al. Three dose regimen of PfSPZ Vaccine protects adult Malians against Plasmodium falciparum through an intense transmission season: a randomized, controlled phase I trial. Lancet Infect Dis. 2021;22:377.","journal-title":"Lancet Infect Dis"},{"key":"7003_CR11","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-021-01470-y","volume":"27","author":"M Oneko","year":"2021","unstructured":"Oneko M, Steinhardt LC, Yego R, Wiegand RE, Swanson PA, Kc N, et\u00a0al. Safety, immunogenicity and efficacy of PfSPZ vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat Med. 2021;27:1636\u201345.","journal-title":"Nat Med"},{"key":"7003_CR12","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.1211548","volume":"334","author":"JE Epstein","year":"2011","unstructured":"Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, et\u00a0al. Live attenuated malaria vaccine designed to protect through hepatic CD8+T cell immunity. Science. 2011;334:475\u201380.","journal-title":"Science"},{"key":"7003_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4269\/ajtmh.2012.12-0613","volume":"88","author":"M Roestenberg","year":"2013","unstructured":"Roestenberg M, Bijker EM, Sim BK, Billingsley PF, James ER, Bastiaens GJ, et\u00a0al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2013;88:5\u201313.","journal-title":"Am J Trop Med Hyg"},{"key":"7003_CR14","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"RA Seder","year":"2013","unstructured":"Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et\u00a0al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341:1359\u201365.","journal-title":"Science"},{"key":"7003_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065960","volume":"8","author":"SH Sheehy","year":"2013","unstructured":"Sheehy SH, Spencer AJ, Douglas AD, Sim BK, Longley RJ, Edwards NJ, et\u00a0al. Optimising controlled human malaria infection studies using cryopreserved parasites administered by needle and syringe. PLoS ONE. 2013;8:e65960.","journal-title":"PLoS ONE"},{"key":"7003_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4269\/ajtmh.14-0119","volume":"91","author":"S Shekalaghe","year":"2014","unstructured":"Shekalaghe S, Rutaihwa M, Billingsley PF, Chemba M, Daubenberger CA, James ER, et\u00a0al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2014;91:471\u201380.","journal-title":"Am J Trop Med Hyg"},{"key":"7003_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2014.00686","volume":"5","author":"SH Hodgson","year":"2014","unstructured":"Hodgson SH, Juma EA, Salim A, Magiri C, Kimani D, Njenga D, et\u00a0al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol. 2014;5:686.","journal-title":"Front Microbiol"},{"key":"7003_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.4269\/ajtmh.15-0621","volume":"94","author":"GJ Bastiaens","year":"2016","unstructured":"Bastiaens GJ, van Meer MP, Scholzen A, Obiero JM, Vatanshenassan M, van Grinsven T, et\u00a0al. Safety, immunogenicity, and protective efficacy of intradermal immunization with aseptic, purified, cryopreserved Plasmodium falciparum sporozoites in volunteers under chloroquine prophylaxis: a randomized controlled trial. Am J Trop Med Hyg. 2016;94:663\u201373.","journal-title":"Am J Trop Med Hyg"},{"key":"7003_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12936-015-0817-x","volume":"14","author":"GP Gomez-Perez","year":"2015","unstructured":"Gomez-Perez GP, Legarda A, Munoz J, Sim BK, Ballester MR, Dobano C, et\u00a0al. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates. Malar J. 2015;14:306.","journal-title":"Malar J"},{"key":"7003_CR20","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.4269\/ajtmh.15-0341","volume":"93","author":"KE Lyke","year":"2015","unstructured":"Lyke KE, Laurens MB, Strauss K, Adams M, Billingsley PF, James E, et\u00a0al. Optimizing intradermal administration of cryopreserved Plasmodium falciparum sporozoites in controlled human malaria infection. Am J Trop Med Hyg. 2015;93:1274\u201384.","journal-title":"Am J Trop Med Hyg"},{"key":"7003_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12936-015-0628-0","volume":"14","author":"B Mordm\u00fcller","year":"2015","unstructured":"Mordm\u00fcller B, Supan C, Sim KL, G\u00f3mez-P\u00e9rez GP, Ospina Salazar CL, Held J, et\u00a0al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J. 2015;14:117.","journal-title":"Malar J"},{"key":"7003_CR22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.4110","volume":"22","author":"AS Ishizuka","year":"2016","unstructured":"Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, et\u00a0al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016;22:614\u201323.","journal-title":"Nat Med"},{"key":"7003_CR23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89154","volume":"2","author":"JE Epstein","year":"2017","unstructured":"Epstein JE, Paolino KM, Richie TL, Sedegah M, Singer A, Ruben AJ, et\u00a0al. Protection against Plasmodium falciparum malaria by PfSPZ vaccine. JCI Insight. 2017;2:e89154.","journal-title":"JCI Insight"},{"key":"7003_CR24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature21060","volume":"542","author":"B Mordm\u00fcller","year":"2017","unstructured":"Mordm\u00fcller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, et\u00a0al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542:445\u20139.","journal-title":"Nature"},{"key":"7003_CR25","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1073\/pnas.1615324114","volume":"114","author":"KE Lyke","year":"2017","unstructured":"Lyke KE, Ishizuka AS, Berry AA, Chakravarty S, DeZure A, Enama ME, et\u00a0al. Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci USA. 2017;114:2711\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7003_CR26","doi-asserted-by":"publisher","first-page":"508","DOI":"10.4269\/ajtmh.17-0343","volume":"98","author":"B Lell","year":"2018","unstructured":"Lell B, Mordm\u00fcller B, Dejon Agobe JC, Honkpehedji J, Zinsou J, Mengue JB, et\u00a0al. Impact of sickle cell trait and naturally acquired immunity on uncomplicated malaria after controlled human malaria infection in adults in Gabon. Am J Trop Med Hyg. 2018;98:508\u201315.","journal-title":"Am J Trop Med Hyg"},{"key":"7003_CR27","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1016\/j.vaccine.2020.05.008","volume":"38","author":"M Oneko","year":"2020","unstructured":"Oneko M, Cherop YR, Sang T, Gutman JR, Wiegand R, Nyang\u2019au EM, et\u00a0al. Feasibility of direct venous inoculation of the radiation-attenuated Plasmodium falciparum whole sporozoite vaccine in children and infants in Siaya, western Kenya. Vaccine. 2020;38:4592\u2013600.","journal-title":"Vaccine"},{"key":"7003_CR28","doi-asserted-by":"publisher","first-page":"e2424","DOI":"10.1093\/cid\/ciaa1294","volume":"73","author":"KE Lyke","year":"2021","unstructured":"Lyke KE, Singer A, Berry AA, Reyes S, Chakravarty S, James ER, et\u00a0al. Multidose priming and delayed boosting improve PfSPZ vaccine efficacy against heterologous P. falciparum controlled human malaria infection. Clin Infect Dis. 2021;73:e2424\u201335.","journal-title":"Clin Infect Dis"},{"key":"7003_CR29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-021-03684-z","volume":"595","author":"A Mwakingwe-Omari","year":"2021","unstructured":"Mwakingwe-Omari A, Healy SA, Lane J, Cook DM, Kalhori S, Wyatt C, et\u00a0al. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature. 2021;595:289\u201394.","journal-title":"Nature"},{"key":"7003_CR30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41541-022-00510-z","volume":"7","author":"B Mordm\u00fcller","year":"2022","unstructured":"Mordm\u00fcller B, Sulyok Z, Sulyok M, Molnar Z, Lalremruata A, Calle CL, et\u00a0al. A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection. NPJ Vaccines. 2022;7:100.","journal-title":"NPJ Vaccines"},{"key":"7003_CR31","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1038\/s41467-021-22740-w","volume":"12","author":"Z Sulyok","year":"2021","unstructured":"Sulyok Z, Fendel R, Eder B, Lorenz FR, Kc N, Karnahl M, et\u00a0al. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nat Commun. 2021;12:2518.","journal-title":"Nat Commun"},{"key":"7003_CR32","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/S1473-3099(24)00360-8","volume":"24","author":"H Diawara","year":"2024","unstructured":"Diawara H, Healy SA, Mwakingwe-Omari A, Issiaka D, Diallo A, Traore S, et\u00a0al. Safety and efficacy of PfSPZ vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2024;24:1366\u201382.","journal-title":"Lancet Infect Dis"},{"key":"7003_CR33","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s44321-024-00057-7","volume":"16","author":"D Goswami","year":"2024","unstructured":"Goswami D, Patel H, Betz W, Armstrong J, Camargo N, Patil A, et\u00a0al. A replication competent Plasmodium falciparum parasite completely attenuated by dual gene deletion. EMBO Mol Med. 2024;16:723\u201354.","journal-title":"EMBO Mol Med"},{"key":"7003_CR34","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1056\/NEJMoa2313892","volume":"391","author":"OA Lamers","year":"2024","unstructured":"Lamers OA, Franke-Fayard BM, Koopman JPR, Roozen GV, Janse JJ, Chevalley-Maurel SC, et\u00a0al. Safety and efficacy of immunization with a late-liver-stage attenuated malaria parasite. N Engl J Med. 2024;391:1913\u201323.","journal-title":"N Engl J Med"},{"key":"7003_CR35","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41591-024-03347-2","volume":"31","author":"GVT Roozen","year":"2025","unstructured":"Roozen GVT, van Schuijlenburg R, Hensen ADO, Koopman JPR, Lamers OAC, Geurten FJA, et\u00a0al. Single immunization with genetically attenuated Pf\u2206mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial. Nat Med. 2025;31:218\u201322.","journal-title":"Nat Med"},{"key":"7003_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/73324","volume":"7","author":"P Orth","year":"2000","unstructured":"Orth P, Schnappinger D, Hillen W, Saenger W, Hinrichs W. Structural basis of gene regulation by the tetracycline inducible Tet repressor-operator system. Nat Struct Biol. 2000;7:215\u20139.","journal-title":"Nat Struct Biol"},{"key":"7003_CR37","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1126\/science.7792603","volume":"268","author":"M Gossen","year":"1995","unstructured":"Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science. 1995;268:1766\u20139.","journal-title":"Science"},{"key":"7003_CR38","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1534\/genetics.104.028175","volume":"167","author":"GJ Lycett","year":"2004","unstructured":"Lycett GJ, Kafatos FC, Loukeris TG. Conditional expression in the malaria mosquito Anopheles stephensi with Tet-On and Tet-Off systems. Genetics. 2004;167:1781\u201390.","journal-title":"Genetics"},{"key":"7003_CR39","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1186\/s12864-017-4385-z","volume":"18","author":"J Bryk","year":"2017","unstructured":"Bryk J, Reeves RG, Reed FA, Denton JA. Transcriptional effects of a positive feedback circuit in Drosophila melanogaster. BMC Genomics. 2017;18:990.","journal-title":"BMC Genomics"},{"key":"7003_CR40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nbt1071","volume":"23","author":"P Gong","year":"2005","unstructured":"Gong P, Epton MJ, Fu G, Scaife S, Hiscox A, Condon KC, et\u00a0al. A dominant lethal genetic system for autocidal control of the Mediterranean fruitfly. Nat Biotechnol. 2005;23:453\u20136.","journal-title":"Nat Biotechnol"},{"key":"7003_CR41","doi-asserted-by":"publisher","first-page":"5547","DOI":"10.1073\/pnas.89.12.5547","volume":"89","author":"M Gossen","year":"1992","unstructured":"Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A. 1992;89:5547\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7003_CR42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev.genet.36.041002.120114","volume":"36","author":"M Gossen","year":"2002","unstructured":"Gossen M, Bujard H. Studying gene function in eukaryotes by conditional gene inactivation. Annu Rev Genet. 2002;36:153\u201373.","journal-title":"Annu Rev Genet"},{"key":"7003_CR43","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.pt.2011.04.004","volume":"27","author":"WCT Black","year":"2011","unstructured":"Black WCT, Alphey L, James AA. Why RIDL is not SIT. Trends Parasitol. 2011;27:362\u201370.","journal-title":"Trends Parasitol."},{"key":"7003_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nbt1283","volume":"25","author":"G Fu","year":"2007","unstructured":"Fu G, Condon KC, Epton MJ, Gong P, Jin L, Condon GC, et\u00a0al. Female-specific insect lethality engineered using alternative splicing. Nat Biotechnol. 2007;25:353\u20137.","journal-title":"Nat Biotechnol"},{"key":"7003_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1741-7007-5-11","volume":"5","author":"HK Phuc","year":"2007","unstructured":"Phuc HK, Andreasen MH, Burton RS, Vass C, Epton MJ, Pape G, et\u00a0al. Late-acting dominant lethal genetic systems and mosquito control. BMC Biol. 2007;5:11.","journal-title":"BMC Biol"},{"key":"7003_CR46","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/d41586-021-01186-6","volume":"593","author":"E Waltz","year":"2021","unstructured":"Waltz E. First genetically modified mosquitoes released in the United States. Nature. 2021;593:175\u20136.","journal-title":"Nature"},{"key":"7003_CR47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12863-020-00947-y","volume":"21","author":"Y Yan","year":"2020","unstructured":"Yan Y, Scott MJ. Building a transgenic sexing strain for genetic control of the Australian sheep blow fly Lucilia cuprina using two lethal effectors. BMC Genet. 2020;21:141.","journal-title":"BMC Genet"},{"key":"7003_CR48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1126\/science.122.3163.287","volume":"122","author":"RC Bushland","year":"1955","unstructured":"Bushland RC, Lindquist AW, Knipling EF. Eradication of screw-worms through release of sterilized males. Science. 1955;122:287\u20138.","journal-title":"Science"},{"key":"7003_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.975786","volume":"10","author":"SAM Spinner","year":"2022","unstructured":"Spinner SAM, Barnes ZH, Puinean AM, Gray P, Dafa\u2019alla T, Phillips CE, et\u00a0al. New self-sexing Aedes aegypti strain eliminates barriers to scalable and sustainable vector control for governments and communities in dengue-prone environments. Front Bioeng Biotechnol. 2022;10:975786.","journal-title":"Front Bioeng Biotechnol"},{"key":"7003_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003864","volume":"9","author":"DO Carvalho","year":"2015","unstructured":"Carvalho DO, McKemey AR, Garziera L, Lacroix R, Donnelly CA, Alphey L, et\u00a0al. Suppression of a field population of Aedes aegypti in Brazil by sustained release of transgenic male mosquitoes. PLoS Negl Trop Dis. 2015;9:e0003864.","journal-title":"PLoS Negl Trop Dis"},{"key":"7003_CR51","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1534\/g3.118.200347","volume":"8","author":"W Reid","year":"2018","unstructured":"Reid W, Pilitt K, Alford R, Cervantes-Medina A, Yu H, Aluvihare C, et\u00a0al. An Anopheles stephensi promoter-trap: augmenting genome annotation and functional genomics. G3 Genes Genomes Genet. 2018;8:3119\u201330.","journal-title":"G3 Genes Genomes Genet"},{"key":"7003_CR52","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.top107686","author":"RA Harrell 2nd","year":"2024","unstructured":"Harrell RA 2nd. Mosquito embryo microinjection. Cold Spring Harb\nProtoc. 2024; https:\/\/doi.org\/10.1101\/pdb.top107686.","journal-title":"Cold Spring Harb Protoc"},{"key":"7003_CR53","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot108203","author":"RA Harrell 2nd","year":"2024","unstructured":"Harrell RA 2nd. Mosquito embryo microinjection under halocarbon oil or\nin aqueous solution. Cold Spring Harb Protoc. 2024; https:\/\/doi.org\/10.1101\/pdb.prot108203.","journal-title":"Cold Spring Harb Protoc"},{"key":"7003_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009770","volume":"17","author":"E Inbar","year":"2021","unstructured":"Inbar E, Eappen AG, Alford RT, Reid W, Harrell RA, Hosseini M, et\u00a0al. Knockout of Anopheles stephensi immune gene LRIM1 by CRISPR-Cas9 reveals its unexpected role in reproduction and vector competence. PLoS Pathog. 2021;17:e1009770.","journal-title":"PLoS Pathog"},{"key":"7003_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010168","volume":"5","author":"CJ Potter","year":"2010","unstructured":"Potter CJ, Luo L. Splinkerette PCR for mapping transposable elements in Drosophila. PLoS ONE. 2010;5:e10168.","journal-title":"PLoS ONE"},{"key":"7003_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030008","volume":"7","author":"RS Linheiro","year":"2012","unstructured":"Linheiro RS, Bergman CM. Whole genome resequencing reveals natural target site preferences of transposable elements in Drosophila melanogaster. PLoS ONE. 2012;7:e30008.","journal-title":"PLoS ONE"},{"key":"7003_CR57","doi-asserted-by":"publisher","first-page":"D898","DOI":"10.1093\/nar\/gkab929","volume":"50","author":"B Amos","year":"2022","unstructured":"Amos B, Aurrecoechea C, Barba M, Barreto A, Basenko EY, Bazant W, et\u00a0al. VEuPathDB: the eukaryotic pathogen, vector and host bioinformatics resource center. Nucleic Acids Res. 2022;50:D898\u2013911.","journal-title":"Nucleic Acids Res"},{"key":"7003_CR58","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with burrows-wheeler transform. Bioinformatics. 2009;25:1754\u201360.","journal-title":"Bioinformatics"},{"key":"7003_CR59","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et\u00a0al. The sequence alignment\/map format and SAMtools. Bioinformatics. 2009;25:2078\u20139.","journal-title":"Bioinformatics"},{"key":"7003_CR60","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan AR, Hall IM. BEDtools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841\u20132.","journal-title":"Bioinformatics"},{"key":"7003_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2199-10-65","volume":"10","author":"PA Papathanos","year":"2009","unstructured":"Papathanos PA, Windbichler N, Menichelli M, Burt A, Crisanti A. The vasa regulatory region mediates germline expression and maternal transmission of proteins in the malaria mosquito Anopheles gambiae: a versatile tool for genetic control strategies. BMC Mol Biol. 2009;10:65.","journal-title":"BMC Mol Biol"},{"key":"7003_CR62","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s13071-020-04216-w","volume":"13","author":"BB Kojin","year":"2020","unstructured":"Kojin BB, Biedler JK, Tu Z, Adelman ZN. Characterization of a female germline and early zygote promoter from the transcription factor bZip1 in the dengue mosquito Aedes aegypti. Parasit Vectors. 2020;13:353.","journal-title":"Parasit Vectors"},{"key":"7003_CR63","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.180208","volume":"8","author":"JS Sun","year":"2018","unstructured":"Sun JS, Xiao S, Carlson JR. The diverse small proteins called odorant-binding proteins. Open Biol. 2018;8:180208.","journal-title":"Open Biol"},{"key":"7003_CR64","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1126\/science.1076196","volume":"298","author":"CA Hill","year":"2002","unstructured":"Hill CA, Fox AN, Pitts RJ, Kent LB, Tan PL, Chrystal MA, et\u00a0al. G protein-coupled receptors in Anopheles gambiae. Science. 2002;298:176\u20138.","journal-title":"Science"},{"key":"7003_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/insects10090278","author":"Z Lyu","year":"2019","unstructured":"Lyu Z, Li Z, Cheng J, Wang C, Chen J, Lin T. Suppression of gene juvenile\nhormone diol kinase delays pupation in Heortia vitessoides Moore. Insects.\n2019; https:\/\/doi.org\/10.3390\/insects10090278.","journal-title":"Insects"},{"key":"7003_CR66","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1126\/science.287.5462.2474","volume":"287","author":"DD Thomas","year":"2000","unstructured":"Thomas DD, Donnelly CA, Wood RJ, Alphey LS. Insect population control using a dominant, repressible, lethal genetic system. Science. 2000;287:2474\u20136.","journal-title":"Science"},{"key":"7003_CR67","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0166-6851(02)00040-3","volume":"121","author":"L Alphey","year":"2002","unstructured":"Alphey L, Andreasen M. Dominant lethality and insect population control. Mol Biochem Parasitol. 2002;121:173\u20138.","journal-title":"Mol Biochem Parasitol"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-025-07003-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-025-07003-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-025-07003-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:08:47Z","timestamp":1761656927000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-025-07003-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7003"],"URL":"https:\/\/doi.org\/10.1186\/s13071-025-07003-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6270709\/v1","asserted-by":"object"}]},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"E.I., T.V.P, G.J., and S.L.H. are salaried employees of Sanaria Inc., the developer and owner of PfSPZ vaccines, and A.E.G. and P.F.B. were salaried employees of Sanaria Inc. when the work was performed. S.L.H. has a financial interest in Sanaria Inc. No other authors have competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"433"}}